Toxicities From Antibody-Drug Conjugates.

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Antibody-drug conjugates (ADCs) are pivotal in modern cancer therapy, integrating targeted antibody delivery with potent cytotoxic payloads.
• Understanding the distinct toxicity profiles of ADCs is crucial, as they extend beyond traditional chemotherapy-related adverse events.

Approach:

• This review synthesizes information on the unique toxicities associated with ADCs, focusing on ocular, pulmonary, dermatologic, and neurologic systems.
• It provides a clinical framework for analyzing current and emerging ADCs based on their structural components: antibody, linker, and payload.

Key Points:

• ADCs possess specific toxicities, including ocular, pulmonary, dermatologic, and neurologic adverse effects, which require specialized management.
• Cytopenias and gastrointestinal issues are common, but nuanced toxicities necessitate distinct monitoring and supportive care strategies.
• Effective management involves proactive identification and intervention for these specific adverse events to optimize patient outcomes.

Conclusions:

• Clinicians require a structured approach to manage the complex toxicity profiles of antibody-drug conjugates.
• Implementing unique monitoring, preventive, and supportive care measures is essential for patients receiving ADC therapy.
• This review serves as a resource for healthcare professionals to navigate the evolving landscape of ADC-related toxicities in cancer treatment.